TY - JOUR
TI - Catatonia as a risk factor for the development of neuroleptic malignant
syndrome: Report of a case following treatment with clozapine
AU - Paparrigopoulos, Thomas
AU - Tzavellas, Elias
AU - Ferentinos, Panagiotis
AU - and Mourikis, Iraklis
AU - Liappas, John
JO - World Journal of Biological Psychiatry
PY - 2009
VL - 10
TODO - 1
SP - 70-73
PB - TAYLOR & FRANCIS LTD LONDON
SN - 1562-2975, 1814-1412
TODO - 10.1080/15622970701287369
TODO - Catatonia; clozapine; neuroleptic malignant syndrome; risk factor
TODO - Catatonia is characterized by the predominance of psychomotor
abnormalities and shares many clinical, biological and treatment
response features with the neuroleptic malignant syndrome (NMS), a rare
adverse reaction to psychoactive medications. It has been advocated that
the two conditions should be placed along the same spectrum of
disorders. A case of a 49-year-old woman, who developed NMS while on low
dose clozapine soon after recovering from catatonia, is presented. The
potential relationship between catatonia and NMS is discussed in the
light of the existing literature, and attention is drawn to the risk for
clozapine-induced NMS in catatonic patients.
ER -